NCT07511361Phase 2Recruiting

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

Study sponsor: Kardigan, Inc. · KARD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-12Estimated
Enrollment · participants140Estimated
Source updated2026-10-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levels Measure: To assess the systolic blood pressure-lowering effect of tonlamarsen. After: Measure: Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions Measure: Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels.

Planned enrollment increased by 40 participants

Before: 100 participants (planned). After: 140 participants (planned).

Primary completion date changed

Before: 29 Dec 2026. After: Dec 2026.

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source